iBio Stock Forecast, Price & News

+0.01 (+0.87 %)
(As of 09/23/2021 11:44 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume1,295 shs
Average Volume9.67 million shs
Market Capitalization$252.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

iBio logo

About iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The firm operates through the iBio, Inc. and iBio CDMO business segments. The company was founded by Robert B. Kay on April 15, 1993 and is headquartered in Bryan, TX.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.83 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Is iBio a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio
or view top-rated stocks.

What stocks does MarketBeat like better than iBio?

Wall Street analysts have given iBio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iBio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Monday, September 27th 2021.
View our earnings forecast for iBio

How can I listen to iBio's earnings call?

iBio will be holding an earnings conference call on Monday, September 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biotechnology company had revenue of $0.77 million for the quarter. iBio had a negative net margin of 895.37% and a negative trailing twelve-month return on equity of 30.81%.
View iBio's earnings history

When did iBio's stock split? How did iBio's stock split work?

Shares of iBio reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

2 analysts have issued 12-month target prices for iBio's shares. Their forecasts range from $2.00 to $3.00. On average, they expect iBio's stock price to reach $2.50 in the next year. This suggests a possible upside of 115.5% from the stock's current price.
View analysts' price targets for iBio
or view top-rated stocks among Wall Street analysts.

Who are iBio's key executives?

iBio's management team includes the following people:
  • Thomas F. Isett, Executive Chairman, President & CEO
  • Randy J. Maddux, Chief Operating Officer
  • Robert M. Lutz, Chief Financial, Accounting & Business Officer
  • Martin B. Brenner, Chief Scientific Officer
  • Robert B. Kay, Secretary, Treasurer & Director

Who are some of iBio's key competitors?

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.14%), Vanguard Group Inc. (4.80%), State Street Corp (1.77%), Geode Capital Management LLC (1.64%), Northern Trust Corp (0.92%) and Susquehanna International Group LLP (0.00%). Company insiders that own iBio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for iBio

Which major investors are selling iBio stock?

IBIO stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., JPMorgan Chase & Co., Bank of America Corp DE, Northern Trust Corp, Millennium Management LLC, Vanguard Group Inc., Price T Rowe Associates Inc. MD, and Invesco Ltd..
View insider buying and selling activity for iBio
or view top insider-selling stocks.

Which major investors are buying iBio stock?

IBIO stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Susquehanna International Group LLP, Squarepoint Ops LLC, Nuveen Asset Management LLC, Geode Capital Management LLC, Marshall Wace LLP, Marshall Wace LLP, and Man Group plc.
View insider buying and selling activity for iBio
or or view top insider-buying stocks.

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.16.

How much money does iBio make?

iBio has a market capitalization of $252.71 million and generates $1.64 million in revenue each year. The biotechnology company earns $-16,440,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does iBio have?

iBio employs 47 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

Where are iBio's headquarters?

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at (302) 355-0650 or via email at [email protected].

This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.